Poly Medicure Limited has informed the Exchange regarding Board meeting held on May 06, 2025.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue grew 22.5% YoY to Rs. 1,601.8 crore, while consolidated revenue rose 23.9% to Rs. 1,691.6 crore. Standalone PAT jumped 31.5% to Rs. 329.8 crore (FY24: Rs. 250.9 crore), and consolidated PAT grew 31% to Rs. 337.2 crore. The board recommended a dividend of Rs. 3.50 per share (70% on face value of Rs. 5) for FY25, subject to shareholder approval. Mr. Vishal Baid was appointed as Executive Director for 5 years, while Mrs. Mukulika Baid stepped down citing personal reasons. PwC and Oswal Sunil & Co were re-appointed as Internal Auditors for FY26, and P.K. Mishra & Associates was appointed as Secretarial Auditor for 5 years. Statutory auditors issued an unmodified (clean) opinion on the results.
Strong double-digit revenue and profit growth, coupled with a healthy 70% dividend, signals robust operational performance and shareholder rewards. Clean audit opinion and stable leadership transition are positive for investor confidence; the stock may see a positive reaction on the back of solid earnings.